On Wednesday, the company informed BSE that CRISIL has upgraded the rating as CRISIL BB-/stable (Upgraded from CRISIL D) for Long Term rating & CRISIL A4+ (Upgraded from CRISIL D) for Short term Rating in respect of Total bank facilities.
Bafna Pharmaceuticals is engaged in the manufacture of drugs and medicines and supplies hi-end pharmaceutical formulations to regulated markets of United Kingdom, Europe and Australia apart from emerging markets like Sri Lanka, Africa and CIS countries etc.
The stock opened at Rs 34.60 and has hit a high of Rs 36.50 till 12:55 hours and around 3,70,000 shares have chnaged hands on BSE and NSE combined.